other material
confidence high
sentiment positive
materiality 0.55
Tonix secures second GPO agreement for TONMYA, expanding commercial coverage to ~52M lives
Tonix Pharmaceuticals Holding Corp.
- Second GPO agreement effective June 1, 2026 adds ~17M US commercial lives (~10% of total).
- Total commercial coverage now ~52M lives (~29% of US commercial lives); first GPO covered ~35M from May 1.
- TONMYA covered under Medicaid in most states (~75M beneficiaries); Medicare discussions ongoing.
- TONMYA (cyclobenzaprine HCl sublingual tablets) approved by FDA Aug 2025 as first new fibromyalgia treatment in over 15 years.